Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00648297 | Fed Study of Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg and Corzide® Tablets 80 mg/5 mg | PHASE1 | COMPLETED | 42 | — | — | Aug 1, 2006 | Aug 1, 2006 | Apr 23, 2024 | 1 | United States |
| NCT00647660 | Fasting Study of Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg and Corzide® Tablets 80 mg/5 mg | PHASE1 | COMPLETED | 66 | — | — | Jul 1, 2006 | Aug 1, 2006 | Apr 23, 2024 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg |
| 2 | ACTIVE_COMPARATOR | Corzide® Tablets 80 mg/5 mg |
| Name | Type | Description |
|---|---|---|
| Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg | DRUG | 80/5mg, single dose fed |
| Corzide® Tablets 80 mg/5 mg | DRUG | 80/5mg, single dose fed |
Inclusion Criteria: 1. Age: 18 years and older 2. Sex: Male and/or non-pregnant, non-lactating female 1. Women of childbearing potential must have negative serum beta human chorionic gonadotropin (β-HCG) pregnancy tests performed within 21 days prior to the start of the study and on the evening...